Andan, Erlinda .

HRN: 25-34-83  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/24/2024
CEFTRIAXONE 1G (VIAL)
06/24/2024
07/01/2024
IV
2g
OD
CAP-MR
Waiting Final Action 
06/24/2024
AZITHROMYCIN 500MG TABLET (TAB)
06/24/2024
06/28/2024
PO
500mg
OD
CAP-MR
Waiting Final Action 
06/30/2024
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
06/30/2024
06/30/2024
IV
4.5gms
SD
CAP HR
Waiting Final Action 
06/30/2024
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
06/30/2024
07/07/2024
IV
2.25gms
Q8
CAP MR
07/01/2024
GENTAMICIN 40MG/ML, 2ML (AMP)
07/01/2024
07/01/2024
IV
80mg
1 Dose
IJ Cath Prophylaxis
Waiting Final Action 
07/08/2024
GENTAMICIN 40MG/ML, 2ML (AMP)
07/08/2024
07/08/2024
IVTT
80mg
Stat Dose
IJ Prophylaxis
Waiting Final Action 
07/10/2024
GENTAMICIN 40MG/ML, 2ML (AMP)
07/10/2024
07/10/2024
IVTT
80mg
Stat Dose
IJ Prophylaxis
Waiting Final Action 
07/11/2024
GENTAMICIN 40MG/ML, 2ML (AMP)
07/11/2024
07/11/2024
IVTT
80 Mg
Stat Dose
IJ Prophylaxis
Waiting Final Action 
07/12/2024
GENTAMICIN 40MG/ML, 2ML (AMP)
07/12/2024
07/12/2024
IV
80mg
STAT
IJ Prophylaxis
Waiting Final Action 
07/13/2024
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
07/13/2024
07/19/2024
IV
2.25g
Q8
CAP-HR Unimproved
Waiting Final Action 
07/13/2024
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
07/13/2024
07/19/2024
TOPICAL
1%
BID
Pressure Blisters Or Ulcers
Waiting Final Action 
07/15/2024
GENTAMICIN 40MG/ML, 2ML (AMP)
07/15/2024
07/15/2024
IV
80mg
Stat
IJ Prophylaxis
Waiting Final Action 
07/17/2024
GENTAMICIN 40MG/ML, 2ML (AMP)
07/17/2024
07/17/2024
IV
80 Mg
Once
IJ Cath Prophylaxis
Waiting Final Action 
07/17/2024
MUPIROCIN 2%, 15G (TUBE)
07/17/2024
07/23/2024
TOPICAL
1 %
OD
Pressure Ulcer
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: